Most recently, the FDA approved TTFields therapy applied concomitant with a PD- 1/PD-L1 inhibitor or docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) that had progressed on or after a platinum-based therapy [36, 37]. The gene discussed is RPL17; the disease is non-small cell lung carcinoma.